Please find enclosed results
ALEMBICLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.3 pts less than Nifty Microcap 250 and 2.9 pts less than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Alembic Limited reported consolidated revenue of Rs 23,999 lakh in FY2026, up 8.2% from Rs 22,189 lakh in FY2025, driven primarily by a 44.6% growth in its Active Pharmaceutical Ingredients (API) business to Rs 4,659 lakh, while the Real Estate segment grew modestly by 2% to Rs 19,340 lakh. Standalone PAT declined 12.3% to Rs 12,454 lakh from Rs 14,195 lakh due to higher tax outgo. However, consolidated net profit after share of associate grew marginally to Rs 31,738 lakh (vs Rs 31,068 lakh), supported by a 15.3% increase in share of associate profit from Alembic Pharmaceuticals Ltd to Rs 19,145 lakh. The company recommended dividend of Rs 2.40 per share (120%). Statutory auditors issued unmodified opinion with an Emphasis of Matter on a contingent liability of Rs 2,052.13 lakh related to a disputed electricity duty matter (with Rs 3,500 lakh deposited with the Hon'ble Supreme Court).
Topline grew at a modest 8% with real estate business showing no growth; standalone PAT declined significantly by 12%, though consolidated PAT was supported by higher associate contribution. The unresolved electricity duty dispute remains a contingent liability risk.